CompletedNot Applicable

Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications

Russia150 participantsStarted 2021-11-01

Plain-language summary

The study is aimed at assessing the role of the activity of high-risk markers of thrombotic events (MCP-1, MIP1α, IP-10, phosphatedylserine, calreticulin) on the development of thrombotic complications in patients with COVID -19.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * men or women over 18 years of age with a new coronavirus infection, confirmed by polymerase chain reaction (PCR) studies and chest CT. Exclusion Criteria: * men or women under 18 years of age; active cancer or a remission period of less than 5 years; decompensated somatic pathology; pregnancy or breastfeeding in women.

What they're measuring

mortality

Timeframe: one year

venous thrombosis or pulmonary embolism

Timeframe: one year

arterial thrombosis

Timeframe: one year

Trial details

NCT IDNCT05143567

SponsorRyazan State Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-23

View on ClinicalTrials.gov More Venous Thromboembolism trials